Business, Companies, coronavirus, earnings, Syngene International

Syngene International on July 21 reported a year-on-year profit after tax of Rs 77.3 crore, a jump of 33 percent in Q1FY22 helped by COVID-19 antiviral medication Remdesivir.

The company reported Rs 58 crore profit in Q1FY21. Revenues rose 39 percent YoY to Rs 607 crore in Q1FY22 compared to Rs 437 crore in the corresponding period of the previous year.

The earnings before interest, tax, depreciation and amortisation (EBITDA) margins stood at 29 percent.

“We made a strong start to the financial year. Besides continuing progress across all our business divisions, growth for the quarter was strongly boosted by the manufacturing of COVID-19 treatment, Remdesivir, as we increased production to meet the needs of the second wave of COVID-19 in India,” said Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene.

“We also made headway with the expansion of our dedicated R&D centre for Bristol Myers Squibb following the contract extension announced last quarter,” Hunt added.

He said that the overall first-quarter performance was in line with its expectations and puts the company on track to meet its full-year growth guidance in the coming quarters.

Business Updates

During the quarter, the biologics business signed a five-year agreement with IAVI, a USA-based, non-profit, scientific research organisation, to develop and manufacture three recombinant, monoclonal antibodies (mAbs) for HIV.

“The mAbs will be used for phase I and II human clinical studies. Under the agreement, Syngene will provide an integrated solution including clone selection, analytical methods development, manufacturing process development, scale-up and cGMP manufacturing of drug substance, viral clearance studies, cGMP manufacturing of drug product and stability studies,” the company said.

Syngene said its scientists continued to work on the coronavirus and have generated several variants of the SARS-CoV2 spike S1 protein including the Alpha and Beta variants. These variants are used to determine the efficacy of different vaccines to cross-protect people from these strains.

John Shaw retires

John Shaw, non-independent director on the Board, and husband of Biocon’s Executive Chairperson Kiran Mazumdar-Shaw will retire due to health reasons, at the end of the 28th Annual General Meeting of the Company, scheduled on July 21.

“John was appointed to the Board in 2000 and has made significant contributions in helping the company cross many significant milestones. His strong management and financial experience helped Syngene establish the strong corporate governance that the company is recognized for,” Syngene said.

Dr Kush Parmar was appointed as a non-executive independent director on the Board effective June 22, 2021, subject to the approval of the shareholders at the AGM scheduled on July 21.

Dr Parmar, a Ph.D. in experimental pathology from Harvard University and an MD from Harvard Medical School, is currently the managing partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco.

Dr Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology and the Grace Science Foundation. At Princeton University, Dr Parmar worked on developmental genetics with Nobel Laureate Eric F. Wieschaus. A founding member of the COVID-19 R&D alliance, Dr Parmar also serves on the Boards of Akouos, Entrada, Homology, Rallybio and Vor Biopharma.


Japan travel news, japan travel guides, japan holiday destinations and japan reviews

LATEST NEWS

NEWS RELATED

Toyota reports over two-fold rise in wholesales in July at 13,105 units

File Image of the Toyota Harrier Toyota Kirloskar Motor (TKM) on July 31 reported over two-fold increase in domestic sales at 13,105 units in July. The automaker, which sells models like Innova, Crysta and Fortuner, had dispatched 5,386 units to its dealerships in July 2020. TKM wholesales in July were…

Read more: Toyota reports over two-fold rise in wholesales in July at 13,105 units

Tata Motors looking at changes in trim mix, direct buying from stockists to deal with chip shortage

(File Image of the Tata Motors Hexa) Tata Motors is looking at various measures, including direct buying from stockists and making changes in the product configurations, to offset the impact of semiconductor shortage on its production activities and sales, a top company official has said. The auto major, which sells…

Read more: Tata Motors looking at changes in trim mix, direct buying from stockists to deal with chip shortage

Tata Motors to look at fund raising for EV business, charts 25% sales from battery-powered cars

Nexon EV – 5 Tata Motors is looking to raise capital for its electric vehicle (EV) business to fuel its ambitious target of generating one-fourth of its sales from EVs in the medium to long term, N Chandrasekaran, Chairman of Tata Motors said at the 76th annual general meeting. The…

Read more: Tata Motors to look at fund raising for EV business, charts 25% sales from battery-powered cars

SC to hear next week Vedanta's plea to continue operating oxygen plant at Tuticorin

The Supreme Court Friday agreed to hear next week Vedanta’s plea seeking to continue operating its oxygen plant at Tuticorin beyond the July 31 deadline set by the top court. A bench of Justices D Y Chandrachud and M R Shah agreed to hear the matter next week after senior…

Read more: SC to hear next week Vedanta's plea to continue operating oxygen plant at Tuticorin

Indian control clause dropped after changes in insurance law, says IRDAI

Insurance Regulatory and Development Authority of India (IRDAI) on July 30 said that the ‘Indian Control of an Indian Insurance Company’ and ‘Indian Ownership’ clause under insurance laws have been dropped with immediate effect. This is after an amendment through the Indian Insurance Companies (Foreign Investment) (Amendment) Rules, 2021. The Insurance…

Read more: Indian control clause dropped after changes in insurance law, says IRDAI

Remain committed to zero debt target by FY24: Tata Motors Chairman N Chandrasekaran at AGM

The sustained surge in demand, improvement in the supply of semiconductors, timely introduction of new products and strict cost-cutting measures will help Tata Motors bring down its debt to zero as committed before, reiterated Chairman N Chandrasekaran at the company’s 76th annual general meeting. “The company declared a goal to…

Read more: Remain committed to zero debt target by FY24: Tata Motors Chairman N Chandrasekaran at AGM

Consumer durable firms expand digital efforts, says Emkay report

An allied area of focus for these companies is the increased emphasis on e-commerce and rural distribution. (Representative image) Consumer durable firms are expanding their digitisation efforts across internal and external verticals, said a report by Emkay Global Financial Services. This is based on their analysis of the FY21 annual…

Read more: Consumer durable firms expand digital efforts, says Emkay report

Hindustan Zinc to invest $1 billion to replace diesel vehicles with battery EVs

Hindustan Zinc Ltd. Mining major Hindustan Zinc Ltd will be investing about USD 1 billion (around Rs 7,440 crore) to replace diesel-run vehicles and equipment with battery electric vehicles across its eight mines in the next five years, company CEO Arun Misra said on Friday. The company, which has signed…

Read more: Hindustan Zinc to invest $1 billion to replace diesel vehicles with battery EVs

Google removes 71,132 content pieces in May, 83,613 items in June in India: Compliance reports

Lupin acquires Melbourne-based drug maker SCP to bolster Australia generics business

Eris Lifesciences on the lookout for acquisitions of brands, product portfolios

Maruti Suzuki plans Rs 4,500 capex in FY22, subject to market realities

Dana Incorporated picks up 1% stake in Switch Mobility for $18 million

Toyota to increase Innova Crysta prices by up to 2% from August

Roche launches Evrysdi, the only approved drug to treat Spinal Muscular Atrophy

Govt says was able to squeeze 4.1 million extra doses of COVID vaccine in May-July from vials

OTHER NEWS